Publications by authors named "Michael Maris"

Claim this Profile

Mentions over time

Mentions by platform

Video Views

21,419

Total Likes

1,031

Extended Reach

111,753

Social Features

9
I
Increased p70s6k phosphorylation during intake of a protein-carbohydrate drink following resistance exercise in the fasted state.
Louise Deldicque, Katrien De Bock, Michael Maris, Monique Ramaekers, Henri Nielens, Marc Francaux, Peter Hespel

March 2010

Videos about Article: user user

2 3 7 4

View All Article and Social Media Activity
C
Comparative Efficacy of Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion Before Chimeric Antigen Receptor T-Cell Therapy in Lymphoma.
Uttam K Rao, Navneet S Majhail, Betsy Blunk, Karin Abernathy, Carlos Bachier, Michael B Maris

Transplant Cell Ther· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
ZUMA-8: a phase 1 study of brexucabtagene autoleucel in patients with relapsed/refractory chronic lymphocytic leukemia.
Matthew S Davids, Saad S Kenderian, Ian Flinn, Brian T Hill, Michael Maris

Blood· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Access barriers to anti-CD19+ CART therapy for NHL across a community transplant and cellular therapy network.
Minoo Battiwalla, Michael Tees, Ian Flinn, Jeremy Pantin, Jesus Berdeja, Michael Maris

Blood Adv· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OUTREACH: phase 2 study of lisocabtagene maraleucel as outpatient or inpatient treatment at community sites for R/R LBCL.
Yuliya Linhares, Cesar O Freytes, Mohamad Cherry, Carlos Bachier, Michael Maris

Blood Adv· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Determinants of Outcomes for Acute Myeloid Leukemia Patients Treated in a Community-Based Specialized Versus Non-Specialized Hospital Setting.
Minoo Battiwalla, Ju-Hsien Chao, Tonya Cox, Jose Carlos Cruz, William B Donnellan, Michael B Maris

Clin Hematol Int· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Michael Maris, Gilles Salles, Won Seog Kim, Tae Min Kim, Roger M Lyons

Target Oncol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardio-renal-metabolic syndrome: clinical features and dapagliflozin eligibility in a real-world heart failure cohort.
Monika Beles, Imke Masuy, Sofie Verstreken, Jozef Bartunek, Riet Dierckx, Michael Maris

ESC Heart Fail· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma.
Kristie A Blum, Jeffrey G Supko, Michael B Maris, Ian W Flinn, Andre Goy

Cancer Res Commun· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Efficacy of a DNA Oligonucleotide Therapy in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Jason Westin, Michael B Maris, Caron A Jacobson, Prapti Patel, Nehal Lakhani

Clin Lymphoma Myeloma Leuk· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I First-in-Human Dose Escalation Study of the oral SF3B1 modulator H3B-8800 in myeloid neoplasms.
David P Steensma, Martin Wermke, Virginia M Klimek, Peter L Greenberg, Patricia Font, Michael B Maris

Leukemia· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical inertia in the treatment of heart failure: a major issue to tackle.
Caroline Verhestraeten, Ward A Heggermont, Michael Maris

Heart Fail Rev· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The in- and out-of-hospital management of HF patients: results from a nationwide Belgian survey.
Liesbeth F Ghys, Pieter Martens, Ward A Heggermont, Laurence Gabriel, Alex Heyse, Michael Maris

Acta Cardiol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Jason P Cooper, Barry E Storer, Noa Granot, Boglark Gyurkocza, Mohamed L Sorror, Michael B Maris

Haematologica· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M Ansell, Michael B Maris, Alexander M Lesokhin, Robert W Chen, Ian W Flinn

Clin Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis, treatment, and follow-up of heart failure patients by general practitioners: A Delphi consensus statement.
Caroline Verhestraeten, Gijs Weijers, Daphne Debleu, Agnieszka Ciarka, Marc Goethals, Michael Maris

PLoS One· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen-mismatched donors.
Brian Kornblit, Barry E Storer, Niels S Andersen, Michael B Maris, Thomas R Chauncey

Blood· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy.
Fevzi F Yalniz, Jesus G Berdeja, Michael B Maris, Roger M Lyons, James A Reeves

Br J Haematol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience.
Mazyar Shadman, David G Maloney, Barry Storer, Brenda M Sandmaier, Thomas R Chauncey, Michael B Maris

Bone Marrow Transplant· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
Ian W Flinn, Mohamad A Cherry, Michael B Maris, Jeffrey V Matous, Jesus G Berdeja

Am J Hematol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
Brenda M Sandmaier, Brian Kornblit, Barry E Storer, Gitte Olesen, Michael B Maris

Lancet Haematol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia.
Ian W Flinn, John G Gribben, Martin J S Dyer, William Wierda, Michael B Maris

Blood· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness and Tolerability of Vildagliptin and the Single Pill Combination of Vildagliptin and Metformin in "Real-World" Management of Type 2 Diabetes Mellitus: The G-FORCE Study.
Luc Van Gaal, Michel P Hermans, Evis Daci, Kris Denhaerynck, Lut De Meester, Michael Maris

Diabetes Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
Ronan T Swords, Steven Coutre, Michael B Maris, Joshua F Zeidner, James M Foran

Blood· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, Guillermo Montalban-Bravo, Jesus G Berdeja, Yasmin Abaza, Elias Jabbour, Michael Maris

Cancer· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.
Jennifer E Vaughn, Mohamed L Sorror, Barry E Storer, Thomas R Chauncey, Michael A Pulsipher, Michael B Maris

Cancer· October 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis